(Q37797464)

23 August 2017

title

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? (English)

1 reference

23 August 2017

0 references

personalized medicine

1 reference

1

Michael Weller

1 reference

23 August 2017

2

Wolfgang Wick

1 reference

23 August 2017

5

Ghazaleh Tabatabai

1 reference

23 August 2017

3

Monika E Hegi

1 reference

23 August 2017

4

Roger Stupp

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1407-1414

1 reference

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

IDH1 mutations in gliomas: when an enzyme loses its grip

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Marker-independent identification of glioma-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Limits of CD133 as a marker of glioma self-renewing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

CD133 is a marker of bioenergetic stress in human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

IFNalpha activates dormant haematopoietic stem cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Methylated tumor-specific DNA as a plasma biomarker in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Serum YKL-40, a new prognostic biomarker in cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Emerging functions of microRNAs in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Improving seroreactivity-based detection of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

21 January 2018

Identifiers

DOI

10.2217/FON.10.113

1 reference

23 August 2017

1 reference